JP2024081668A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024081668A5 JP2024081668A5 JP2024034617A JP2024034617A JP2024081668A5 JP 2024081668 A5 JP2024081668 A5 JP 2024081668A5 JP 2024034617 A JP2024034617 A JP 2024034617A JP 2024034617 A JP2024034617 A JP 2024034617A JP 2024081668 A5 JP2024081668 A5 JP 2024081668A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- indicates
- antisense strand
- rnai oligonucleotide
- ome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061676P | 2020-08-05 | 2020-08-05 | |
| US63/061,676 | 2020-08-05 | ||
| US202063074779P | 2020-09-04 | 2020-09-04 | |
| US63/074,779 | 2020-09-04 | ||
| PCT/US2021/071109 WO2022032288A1 (en) | 2020-08-05 | 2021-08-05 | Compositions and methods for inhibiting lpa expression |
| JP2023507767A JP7476422B2 (ja) | 2020-08-05 | 2021-08-05 | Ｌｐａ発現を阻害するための組成物及び方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507767A Division JP7476422B2 (ja) | 2020-08-05 | 2021-08-05 | Ｌｐａ発現を阻害するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024081668A JP2024081668A (ja) | 2024-06-18 |
| JP2024081668A5 true JP2024081668A5 (https=) | 2024-08-13 |
| JP7805386B2 JP7805386B2 (ja) | 2026-01-23 |
Family
ID=77519885
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507767A Active JP7476422B2 (ja) | 2020-08-05 | 2021-08-05 | Ｌｐａ発現を阻害するための組成物及び方法 |
| JP2024034617A Active JP7805386B2 (ja) | 2020-08-05 | 2024-03-07 | Ｌｐａ発現を阻害するための組成物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507767A Active JP7476422B2 (ja) | 2020-08-05 | 2021-08-05 | Ｌｐａ発現を阻害するための組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US12435336B2 (https=) |
| EP (1) | EP4192954A1 (https=) |
| JP (2) | JP7476422B2 (https=) |
| KR (2) | KR102812602B1 (https=) |
| CN (1) | CN116323943A (https=) |
| AU (2) | AU2021320550B2 (https=) |
| BR (1) | BR112023001957A2 (https=) |
| CA (1) | CA3185348A1 (https=) |
| IL (1) | IL300338A (https=) |
| MX (1) | MX2023001538A (https=) |
| TW (2) | TWI886314B (https=) |
| WO (1) | WO2022032288A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102812602B1 (ko) | 2020-08-05 | 2025-05-28 | 다이서나 파마수이티컬, 인크. | Lpa 발현을 저해하기 위한 조성물 및 방법 |
| IL312811A (en) | 2021-11-16 | 2024-07-01 | Shanghai Argo Biopharmaceutical Co Ltd | Composition and method for inhibiting angiotensinogen (agt) protein expression |
| WO2023109940A1 (zh) * | 2021-12-16 | 2023-06-22 | 上海拓界生物医药科技有限公司 | 靶向lpa的sirna及缀合物 |
| CN114703184B (zh) * | 2022-03-11 | 2024-06-18 | 厦门甘宝利生物医药有限公司 | Lpa抑制剂及其用途 |
| KR20250005108A (ko) * | 2022-04-15 | 2025-01-09 | 다이서나 파마수이티컬, 인크. | Scap 활성을 조절하기 위한 조성물 및 방법 |
| KR20250087521A (ko) * | 2022-08-11 | 2025-06-16 | 시리우스 테라퓨틱스, 인크. | Lp(a)의 발현을 억제하기 위한 다중핵산 분자, 약제학적 조성물 및 이의 용도 |
| CN115851723B (zh) * | 2022-10-24 | 2023-10-03 | 厦门甘宝利生物医药有限公司 | 一种抑制lpa基因表达的rna抑制剂及其应用 |
| AU2023384015A1 (en) | 2022-11-23 | 2025-05-22 | Eli Lilly And Company | Methods of synthesizing a targeting ligand-conjugated nucleotide phosphoramidite |
| CN120239704A (zh) | 2022-11-23 | 2025-07-01 | 伊莱利利公司 | 合成4'-磷酸盐类似物核苷酸亚磷酰胺的方法 |
| AU2023408776A1 (en) | 2022-12-22 | 2025-07-10 | Eli Lilly And Company | Oligonucleotide fragments and methods of making rnai agents using the same |
| IL321855A (en) | 2023-01-13 | 2025-08-01 | Lilly Co Eli | Pharmaceutical preparations containing therapeutic oligonucleotides and dosage regimens using the same |
| KR20250163949A (ko) * | 2023-03-20 | 2025-11-21 | 버브 테라퓨틱스, 인크. | 심혈관 질환의 치료를 위한 lpa 유전자의 생체내 닉카제-기반 편집 |
| CN118685405A (zh) * | 2023-06-20 | 2024-09-24 | 施能康医药科技(苏州)有限公司 | 靶向脂蛋白a的核酸及其用途 |
| WO2025064821A2 (en) | 2023-09-21 | 2025-03-27 | Ionis Pharmaceuticals, Inc. | Compounds and methods for inhibiting lpa |
| WO2025082058A1 (zh) * | 2023-10-16 | 2025-04-24 | 润佳(上海)医药技术有限公司 | 一种抑制LPA基因表达的dsRNA及其用途 |
| WO2025087442A1 (zh) * | 2023-10-27 | 2025-05-01 | 北京安龙生物医药有限公司 | 靶向脂蛋白a的寡核苷酸及其用途 |
| CN120020252A (zh) * | 2023-11-17 | 2025-05-20 | 纳肽得(青岛)生物医药有限公司 | 抑制LPA表达的siRNA及其用途 |
| WO2025117709A2 (en) * | 2023-11-29 | 2025-06-05 | Sanegene Bio Usa Inc. | Small interfering rna targeting lp(a) and uses thereof |
| CN120098993A (zh) * | 2023-12-05 | 2025-06-06 | 广东东阳光药业股份有限公司 | 一种新型的双链siRNA、其缀合物及其用途 |
| WO2025170868A1 (en) * | 2024-02-05 | 2025-08-14 | Sirius Therapeutics, Inc. | Polynucleic acid molecules for inhibiting expression of lp(a) or apoc3, pharmaceutical compositions, and uses thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6469158B1 (en) | 1992-05-14 | 2002-10-22 | Ribozyme Pharmaceuticals, Incorporated | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| US5977343A (en) | 1992-05-14 | 1999-11-02 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| US5804683A (en) | 1992-05-14 | 1998-09-08 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA with alkylamine |
| WO1995006731A2 (en) | 1993-09-02 | 1995-03-09 | Ribozyme Pharmaceuticals, Inc. | Non-nucleotide containing enzymatic nucleic acid |
| US5889136A (en) | 1995-06-09 | 1999-03-30 | The Regents Of The University Of Colorado | Orthoester protecting groups in RNA synthesis |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US6111086A (en) | 1998-02-27 | 2000-08-29 | Scaringe; Stephen A. | Orthoester protecting groups |
| PT1309726E (pt) | 2000-03-30 | 2010-03-08 | Whitehead Biomedical Inst | Mediadores de interferência por rna específicos de sequência de rna |
| US20040259247A1 (en) | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US20050159378A1 (en) | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
| JP2005508196A (ja) | 2001-11-07 | 2005-03-31 | アプレラ コーポレイション | 核酸分析の汎用ヌクレオチド |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| WO2007030167A1 (en) | 2005-09-02 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Modification of double-stranded ribonucleic acid molecules |
| JP2012504389A (ja) | 2008-09-22 | 2012-02-23 | ダイセルナ ファーマシューティカルズ， インコーポレイテッド | 修飾を有するｄｓＲＮＡによる遺伝子発現の特異的な阻害のための組成物および方法 |
| US8691971B2 (en) | 2008-09-23 | 2014-04-08 | Scott G. Petersen | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference |
| AU2009336191B2 (en) | 2008-12-18 | 2017-08-24 | Novo Nordisk A/S | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| US8927513B2 (en) | 2009-07-07 | 2015-01-06 | Alnylam Pharmaceuticals, Inc. | 5′ phosphate mimics |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| JP2015501155A (ja) | 2011-10-25 | 2015-01-15 | アイシス ファーマシューティカルズ， インコーポレーテッド | Ｇｃｃｒ発現のアンチセンス調整 |
| EP2928877B1 (en) | 2012-12-06 | 2020-01-22 | Merck Sharp & Dohme Corp. | Disulfide masked prodrug compositions and methods |
| JP2017522046A (ja) | 2014-06-06 | 2017-08-10 | ソルスティス バイオロジクス，リミティッド | 生物可逆的および生物不可逆的基を有するポリヌクレオチド構築物 |
| JP7105065B2 (ja) | 2014-12-15 | 2022-07-22 | ダイセルナ ファーマシューティカルズ， インコーポレイテッド | リガンド修飾二本鎖核酸 |
| JOP20160211B1 (ar) * | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| KR102350647B1 (ko) | 2016-09-02 | 2022-01-14 | 다이서나 파마수이티컬, 인크. | 4'-포스페이트 유사체 및 이를 포함하는 올리고뉴클레오타이드 |
| MX2020004897A (es) | 2017-11-13 | 2020-10-05 | Silence Therapeutics Gmbh | Acidos nucleicos para inhibir la expresion de lpa en una celula. |
| AR113490A1 (es) * | 2017-12-12 | 2020-05-06 | Amgen Inc | CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS |
| US20230078200A1 (en) | 2019-12-09 | 2023-03-16 | Amgen Inc. | RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION |
| KR102812602B1 (ko) | 2020-08-05 | 2025-05-28 | 다이서나 파마수이티컬, 인크. | Lpa 발현을 저해하기 위한 조성물 및 방법 |
-
2021
- 2021-08-05 KR KR1020237006019A patent/KR102812602B1/ko active Active
- 2021-08-05 CN CN202180058046.7A patent/CN116323943A/zh active Pending
- 2021-08-05 TW TW110128888A patent/TWI886314B/zh active
- 2021-08-05 AU AU2021320550A patent/AU2021320550B2/en active Active
- 2021-08-05 CA CA3185348A patent/CA3185348A1/en active Pending
- 2021-08-05 JP JP2023507767A patent/JP7476422B2/ja active Active
- 2021-08-05 TW TW114118397A patent/TW202535432A/zh unknown
- 2021-08-05 EP EP21762318.0A patent/EP4192954A1/en active Pending
- 2021-08-05 US US18/040,302 patent/US12435336B2/en active Active
- 2021-08-05 BR BR112023001957A patent/BR112023001957A2/pt unknown
- 2021-08-05 IL IL300338A patent/IL300338A/en unknown
- 2021-08-05 MX MX2023001538A patent/MX2023001538A/es unknown
- 2021-08-05 KR KR1020257016689A patent/KR20250077604A/ko active Pending
- 2021-08-05 WO PCT/US2021/071109 patent/WO2022032288A1/en not_active Ceased
-
2024
- 2024-03-07 JP JP2024034617A patent/JP7805386B2/ja active Active
- 2024-08-16 US US18/807,591 patent/US12252691B2/en active Active
-
2025
- 2025-08-04 US US19/290,213 patent/US20260071219A1/en active Pending
- 2025-10-17 AU AU2025252633A patent/AU2025252633A1/en active Pending